In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
Notes from the Asia-Pacific region: Advancing understanding, management of personal data a worthy task
Why health care privacy is a mess — and why it isn't likely to get better soon
A look at stakeholder input for the White House AI action plan
A view from Brussels: Privacy and competition walk into a bar
Removal of FTC commissioners fuels uncertainty
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.